BioWorld

Feb. 10, 2009

Lundbeck Gains U.S. Foothold in $900M Deal for Ovation

Danish drugmaker H. Lundbeck A/S plans to buy U.S. biotech Ovation Pharmaceuticals in a proposed $900 million deal that would give the Copenhagen-based company access to the U.S. commercial market. (BioWorld Today) Read More

Investors Seeing Positive Side for Biotech in Bleak Economy

Panel: Keep Options Open to Survive Troubled Times

ViroPharma Shares Halved as Maribavir Fails Phase III Trial

Alliance Management Plays Important Role in Avoiding Failure

Lobbying Dynamics Reveal New Trends in Power

Gilded Age Can Be Ushered in by Biopartnered Gene Therapies

Corrections & Clarifications

Dynavax Soars on Possibility of Regulatory Path for Heplisav

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026